These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15553667)

  • 41. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy.
    Kitamura H; Torigoe T; Honma I; Asanuma H; Nakazawa E; Shimozawa K; Hirohashi Y; Sato E; Sato N; Tsukamoto T
    Urology; 2006 May; 67(5):955-9. PubMed ID: 16635519
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
    Weihrauch MR; Ansén S; Jurkiewicz E; Geisen C; Xia Z; Anderson KS; Gracien E; Schmidt M; Wittig B; Diehl V; Wolf J; Bohlen H; Nadler LM
    Clin Cancer Res; 2005 Aug; 11(16):5993-6001. PubMed ID: 16115944
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
    Duggan MC; Jochems C; Donahue RN; Richards J; Karpa V; Foust E; Paul B; Brooks T; Tridandapani S; Olencki T; Pan X; Lesinski GB; Schlom J; Carson Iii WE
    Cancer Immunol Immunother; 2016 Nov; 65(11):1353-1364. PubMed ID: 27581603
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.
    Ueda Y; Itoh T; Nukaya I; Kawashima I; Okugawa K; Yano Y; Yamamoto Y; Naitoh K; Shimizu K; Imura K; Fuji N; Fujiwara H; Ochiai T; Itoi H; Sonoyama T; Hagiwara A; Takesako K; Yamagishi H
    Int J Oncol; 2004 Apr; 24(4):909-17. PubMed ID: 15010829
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides.
    Miyagi Y; Imai N; Sasatomi T; Yamada A; Mine T; Katagiri K; Nakagawa M; Muto A; Okouchi S; Isomoto H; Shirouzu K; Yamana H; Itoh K
    Clin Cancer Res; 2001 Dec; 7(12):3950-62. PubMed ID: 11751487
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
    Oji Y; Hashimoto N; Tsuboi A; Murakami Y; Iwai M; Kagawa N; Chiba Y; Izumoto S; Elisseeva O; Ichinohasama R; Sakamoto J; Morita S; Nakajima H; Takashima S; Nakae Y; Nakata J; Kawakami M; Nishida S; Hosen N; Fujiki F; Morimoto S; Adachi M; Iwamoto M; Oka Y; Yoshimine T; Sugiyama H
    Int J Cancer; 2016 Sep; 139(6):1391-401. PubMed ID: 27170523
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
    Sawada Y; Yoshikawa T; Nobuoka D; Shirakawa H; Kuronuma T; Motomura Y; Mizuno S; Ishii H; Nakachi K; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Takayama T; Yamao K; Uesaka K; Furuse J; Kinoshita T; Nakatsura T
    Clin Cancer Res; 2012 Jul; 18(13):3686-96. PubMed ID: 22577059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Preliminary study of Peptide vaccine with UFT/LV as adjuvant setting for stage III colorectal cancer].
    Okuno K; Sugiura F; Hida J; Tokoro T; Ishimaru E; Ueda K
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1906-8. PubMed ID: 22202234
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles.
    Bachinsky MM; Guillen DE; Patel SR; Singleton J; Chen C; Soltis DA; Tussey LG
    Cancer Immun; 2005 Mar; 5():6. PubMed ID: 15779886
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
    Nagaraj S; Pisarev V; Kinarsky L; Sherman S; Muro-Cacho C; Altieri DC; Gabrilovich DI
    J Immunother; 2007; 30(2):169-79. PubMed ID: 17471164
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.
    Speetjens FM; Kuppen PJ; Welters MJ; Essahsah F; Voet van den Brink AM; Lantrua MG; Valentijn AR; Oostendorp J; Fathers LM; Nijman HW; Drijfhout JW; van de Velde CJ; Melief CJ; van der Burg SH
    Clin Cancer Res; 2009 Feb; 15(3):1086-95. PubMed ID: 19188184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes.
    Køllgaard T; Ugurel-Becker S; Idorn M; Andersen MH; Becker JC; Straten PT
    PLoS One; 2015; 10(7):e0131934. PubMed ID: 26176858
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer.
    Shindo Y; Hazama S; Suzuki N; Iguchi H; Uesugi K; Tanaka H; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Takenouchi H; Matsui H; Kanekiyo S; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Fujita T; Kawakami Y; Nakamura Y; Oka M; Nagano H
    J Exp Clin Cancer Res; 2017 Feb; 36(1):36. PubMed ID: 28241889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC).
    Ling X; Yang J; Tan D; Ramnath N; Younis T; Bundy BN; Slocum HK; Yang L; Zhou M; Li F
    Lung Cancer; 2005 Sep; 49(3):353-61. PubMed ID: 15936846
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer.
    Chen JS; Chen KT; Fan WC; Yu JS; Chang YS; Chan EC
    Clin Chem Lab Med; 2010 May; 48(5):719-25. PubMed ID: 20178447
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.
    Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    Int Immunopharmacol; 2014 May; 20(1):59-65. PubMed ID: 24583149
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
    Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
    J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients.
    Chang JT; Wong FH; Liao CT; Chen IH; Wang HM; Cheng AJ
    Clin Chem; 2004 Jul; 50(7):1261-4. PubMed ID: 15229162
    [No Abstract]   [Full Text] [Related]  

  • 59. Peptide vaccinations elicited strong immune responses that were reboosted by anti-PD1 therapy in a patient with myxofibrosarcoma.
    Tsukahara T; Watanabe K; Murata K; Takahashi A; Mizushima E; Shibayama Y; Kameshima H; Hatae R; Ohno Y; Kawahara R; Murai A; Nakatsugawa M; Kubo T; Kanaseki T; Hirohashi Y; Terui T; Asanuma H; Hasegawa T; Sato N; Torigoe T
    Cancer Immunol Immunother; 2020 Feb; 69(2):189-197. PubMed ID: 31853575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Detection of autoantibody against cancer antigen and its clinical application].
    Yagihashi A
    Nihon Naika Gakkai Zasshi; 2006 Jul; 95(7):1382-6. PubMed ID: 16893037
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.